Get the Stockscreener App
58.22
14.63%
-9.98
After Hours:
58.24
0.02
+0.03%
Dexcom Inc stock is traded at $58.22, with a volume of 26.55M.
It is down -14.63% in the last 24 hours and down -13.48% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$68.20
Open:
$59.19
24h Volume:
26.55M
Relative Volume:
4.92
Market Cap:
$22.83B
Revenue:
$4.30B
Net Income/Loss:
$571.50M
P/E Ratio:
40.76
EPS:
1.4285
Net Cash Flow:
$570.80M
1W Performance:
-17.22%
1M Performance:
-13.48%
6M Performance:
-18.44%
1Y Performance:
-17.40%
1-Day Range:
$56.45
$60.36
1-Week Range:
$56.45
$71.11
52-Week Range:
$56.45
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
58.22 | 26.74B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
123.62 | 216.79B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
100.72 | 149.02B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
356.24 | 141.06B | 24.38B | 2.94B | 4.02B | 7.6145 |
|
MDT
Medtronic Plc
|
90.70 | 116.68B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
82.45 | 49.01B | 5.88B | 1.34B | 577.90M | 2.3455 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Will breakout in DexCom Inc. lead to full recoveryTrade Volume Report & Capital Protection Trade Alerts - newser.com
Is DexCom Inc. (DC4) stock a top pick for value investorsIPO Watch & Reliable Entry Point Alerts - newser.com
DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (DXCM)Contact Kessler Topaz Meltzer & Check, LLP - PR Newswire
Earnings Beat: DexCom, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st
Geneva Capital Management LLC Increases Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Is DexCom Inc. (DC4) stock a buy for dividend portfoliosCPI Data & Capital Protection Trade Alerts - newser.com
DexCom, Inc. $DXCM Shares Acquired by Strs Ohio - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Q3 2025 Earnings Call Transcript - MSN
Is DexCom Inc. (DC4) stock supported by free cash flowQuarterly Investment Review & Stepwise Entry/Exit Trade Alerts - newser.com
DexCom (NASDAQ:DXCM) Price Target Lowered to $75.00 at JPMorgan Chase & Co. - MarketBeat
What catalysts could drive DexCom Inc. stock higherWeekly Loss Report & Precise Swing Trade Entry Alerts - newser.com
Will DexCom Inc. stock maintain momentum in 2025Weekly Profit Recap & Smart Allocation Stock Tips - newser.com
DexCom (DXCM): Net Margin Slides to 13.3%, Testing Bulls’ Profitability Narratives - Yahoo Finance
Class Action Announcement for DexCom, Inc. (DXCM): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against DexCom, Inc. - GlobeNewswire Inc.
Royal Bank Of Canada Cuts DexCom (NASDAQ:DXCM) Price Target to $85.00 - MarketBeat
DexCom (NASDAQ:DXCM) Shares Gap Down After Analyst Downgrade - MarketBeat
DexCom (NASDAQ:DXCM) Price Target Lowered to $85.00 at BTIG Research - MarketBeat
Fisher Funds Management LTD Sells 339,084 Shares of DexCom, Inc. $DXCM - MarketBeat
Hantz Financial Services Inc. Trims Stake in DexCom, Inc. $DXCM - MarketBeat
Envestnet Asset Management Inc. Increases Stock Position in DexCom, Inc. $DXCM - MarketBeat
Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 2025 - ADVFN
What MACD trends signal for DexCom Inc. (DC4) stockQuarterly Portfolio Summary & Weekly High Return Stock Opportunities - newser.com
Citigroup Maintains DexCom (DXCM) Buy Recommendation - Nasdaq
JP Morgan Maintains DexCom (DXCM) Neutral Recommendation - Nasdaq
Dexcom’s revenue is up, but sensor scrap issue hit margins - Modern Healthcare
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Malaysian Reserve
DexCom (NASDAQ:DXCM) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
DexCom (DXCM): Canaccord Genuity Lowers Price Target to $99.00 | DXCM Stock News - GuruFocus
DexCom (DXCM): Canaccord Genuity Lowers Price Target to $99.00 | - GuruFocus
DexCom Inc (DXCM) Stock Price, Trades & News - GuruFocus
DexCom (DXCM): Citigroup Lowers Price Target to $75 while Mainta - GuruFocus
Halloween turns scary for Dexcom despite strong Q3 - BioWorld MedTech
Amazon Jumps, First Solar Shines, DexCom Drops In Busy Quarter - Finimize
S&P 500 Gains and Losses Today: Amazon Stock Surges as Cloud Business Boosts Earnings; DexCom Drops - Investopedia
JP Morgan Lowers Price Target for DexCom (DXCM) to $75, Maintain - GuruFocus
DexCom Stock Falls Despite Q3 Earnings Beat, 2025 Revenue View Raised - sharewise.com
Why DexCom Stock Is Crashing Today - sharewise.com
DexCom (DXCM) Shares Drop Despite Strong Q3 Results and Revenue Guidance Boost - GuruFocus
DexCom’s Shares Drop Despite Beating Earnings Expectations - Finimize
Why DexCom (DXCM) Stock Is Falling Today - Yahoo Finance
DXCM Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against DexCom, Inc. - The AI Journal
Traders Purchase High Volume of DexCom Call Options (NASDAQ:DXCM) - MarketBeat
Shareholders who lost money in shares of DexCom, Inc. - GlobeNewswire
DexCom slips after earnings on margin trends, 2026 growth concerns - Seeking Alpha
DexCom stock hits 52-week low at 57.5 USD By Investing.com - Investing.com Nigeria
DexCom stock hits 52-week low at 57.5 USD - Investing.com
Important Notice to Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR); DexCom, Inc. (NASDAQ: ... - Bluefield Daily Telegraph
Important Notice to Long-Term Shareholders of Avantor, Inc. - GlobeNewswire
Dexcom execs say company has fixed G7 quality problems - MedTech Dive
DexCom Stock Is the Worst Performer in the S&P 500. Here’s Why. - Barron's
Dexcom shares extend fall over 2026 growth concerns - TradingView
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):